Cited by 2,029Nanoparticle-Based Drug DeliveryNanotechnology research and applicationsPharmacology and Nanomedicine Research

Nanomedicine: current status and future prospects

Moghimi, S. Moein, Hunter, A. Christy, Murray, J. Clifford·2005·The FASEB Journal

Abstract

Applications of nanotechnology for treatment, diagnosis, monitoring, and control of biological systems has recently been referred to as “nanomedicine” by the National Institutes of Health. Research into the rational delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine. These involve the identification of precise targets (cells and receptors) related to specific clinical conditions and choice of the appropriate nanocarriers to achieve the required responses while minimizing the side effects. Mononuclear phagocytes, dendritic cells, endothelial cells, and cancers (tumor cells, as well as tumor neovasculature) are key targets. Today, nanotechnology and nanoscience approaches to particle design and formulation are beginning to expand the market for many drugs and are forming the basis for a highly profitable niche within the industry, but some predicted benefits are hyped. This article will highlight rational approaches in design and surface engineering of nanoscale vehicles and entities for site‐specific drug delivery and medical imaging after parenteral administration. Potential pitfalls or side effects associated with nanoparticles are also discussed.—Moghimi, S. M. Hunter, A. C., Murray, J. C. Nanomedicine: current status and future prospects. FASEB J. 19, 311‐330 (2005)

Integrity signals

Registry

Crossref · 10.1096/fj.04-2747rev

Cites

164 of 164 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Primary rationale of using a suitable drug delivery system is its ability to ensure higher and longer duration of drug bioavailability and thereby enhanced therapeutic efficacy.

    “The primary rationale of using a suitable drug delivery system is its ability to ensure a higher and longer duration of drug bioavailability and thereby enhanced therapeutic efficacy.14,15”

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Moghimi, S. M., Hunter, A. C., & Murray, J. C.
Affiliations
  • University of Brighton (GB)
  • Cancer Research UK (GB)
Venue
The FASEB Journal
Publisher
Wiley
Published
2005-03
Volume
19
Issue
3
Pages
311-330
ISSN
  • 0892-6638 (ISSN-L)
  • 1530-6860
OpenAlex
W2111115146
Cited by
2,029
References
164
Citations by year
2026: 42 · 2025: 54 · 2024: 54 · 2023: 76 · 2022: 84 · 2021: 78 · 2020: 85 · 2019: 89 · 2018: 102 · 2017: 140 · 2016: 131 · 2015: 123 · 2014: 134 · 2013: 121 · 2012: 128
FWCI
5.58
Type
journal article
Language
en
Open access
closed
Locations
  • The FASEB Journal (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • University of Brighton Repository (University of Brighton) (submittedVersion)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanotechnology research and applications
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
Keywords
nanomedicine, nanocarriers, targeted drug delivery, local drug delivery, nanoparticle surface modification, diagnostic imaging, dendritic cells, tumor neovasculature, mononuclear phagocytes, endothelial cells, nanoparticle toxicity, parenteral administration
MeSH terms
Blood Vessels, Diagnosis, Drug Administration Routes, Drug Hypersensitivity, Drug Industry, Drug Therapy, Endothelium, Vascular, Humans, Lymphatic System, Macrophages, Microscopy, Electron, Scanning, National Institutes of Health (U.S.), Neoplasms, Particle Size, Technology, Pharmaceutical, United States, Drug Delivery Systems, Nanotechnology, Nanostructures, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review